Biofabri was founded in 2008 with a vision: to research and develop human vaccines.
As a biopharmaceutical company focused on human health, we possess strong technical and
development capabilities, as well as a proven track record.
Biofabri actively collaborated on the urgent development of solutions against
COVID-19 through our research capabilities in several projects.
Our business model is centered around continuous innovation in the field of biotechnology. We are committed to preventive medicine and our goal is to develop a range of vaccines for the prevention of some of the most relevant diseases today. To achieve this, we invest heavily in research and development and have a highly experienced team of specialized scientists.
The company has an extensive experience in researching and developing innovative and ambitious projects that include different vaccine technologies against viral, bacterial and parasitic diseases:
- Classic vaccines
- Genetically engineered live attenuated vaccines
- Subunit vaccines (recombinant protein)
- Latest generation RNA and DNA Vaccines
R&D department has modern facilities and state-of-the-art equipment and collaborates closely with universities and research centers of recognized national and international prestige.
Contract development and manufacturing services for any company looking to develop and
manufacture biologics, from the development phase to clinical phases I to III, as well as
CZ Vaccines is a company within the Zendal Group that specializes in the development and
manufacturing of vaccines and other biological products.